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Abstract
Introduction: Interleukin-22 (IL-22) is a cytokine of IL-10 family with significant proliferative effect on different cell
lines. Immunopathological role of IL-22 has been studied in rheumatoid arthritis (RA) and psoriasis. Here we are
reporting the functional role of IL-22 in the inflammatory and proliferative cascades of psoriatic arthritis (PsA).
Method: From peripheral blood and synovial fluid (SF) of PsA (n = 15), RA (n = 15) and osteoarthritis (OA, n = 15)
patients, mononuclear cells were obtained and magnetically sorted for CD3+ T cells. Fibroblast like synoviocytes
(FLS) were isolated from the synovial tissue of PsA (n = 5), RA (n = 5) and OA (n = 5) patients. IL-22 levels in SF
and serum were measured by enzyme linked immunosorbent assay (ELISA). Proliferative effect of human
recombinant IL-22 (rIL-22) on FLS was assessed by MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide, a yellow tetrazole) and CFSE dilution (Carboxyfluorescein succinimidyl ester) assays. Expression of IL-
22Ra1 in FLS was determined by western blot.
Results: IL-22 levels were significantly elevated in SF of PsA patients (17.75 ± 3.46 pg/ml) compared to SF of OA
(5.03 ± 0.39 pg/ml), p < 0.001. In MTT and CFSE dilution assays, rIL-22 (MTT, OD: 1.27 ± 0.06) induced significant
proliferation of FLS derived from PsA patients compared to media (OD: 0.53 ± 0.02), p < 0.001. In addition, rIL-22
induced significantly more proliferation of FLS in presence of TNF-a. IL-22Ra1 was expressed in FLS of PsA, RA and
OA patients. Anti IL-22R antibody significantly inhibited the proliferative effect of rIL-22. Further we demonstrated
that activated synovial T cells of PsA and RA patients produced significantly more IL-22 than those of OA patients.
Conclusion: SF of PsA patients have higher concentration of IL-22 and rIL-22 induced marked proliferation of PsA
derived FLS. Moreover combination of rIL-22 and TNF-a showed significantly more proliferative effect on FLS. IL-
22Ra1 was expressed in FLS. Successful inhibition of IL-22 induced FLS proliferation by anti IL-22R antibody
suggests that blocking of IL-22/IL-22R interaction may be considered as a novel therapeutic target for PsA.
Introduction
Psoriatic arthritis (PsA) is an inflammatory arthritis
associated with psoriasis [1,2]. The role of genetic,
immunological and environmental factors in the patho-
genesis of PsA has been proposed, however the exact
cause remains to be determined [3,4]. In the joint of
PsA patients, there is hyperplasia of synovial lining cells
and infiltration of mononuclear cells, which plays an
important role in disease pathogenesis [5]. In PsA acti-
vated T cells produce increased amount of pro-inflam-
matory cytokines like IL-1b, IL-2, IFN-g, TNF-a and IL-
17 in the synovial fluid (SF) and thus contribute signifi-
cantly to the disease pathogenesis [6-8]. Moreover
fibroblasts isolated from skin and joints of patients with
PsA showed increased proliferative activity and are cap-
able of secreting IL-6, IL-1 and platelet derived growth
factor [9]. It was reported previously that Th1 cytokines
like IL-1b, TNF-a were higher in PsA compared to
rheumatoid arthritis (RA) [6]. Recent findings suggest
that there is hardly any difference in Th1 cytokines
among these two groups [10]. The pro-inflammatory
cytokine, TNF-a stimulates the proliferation of synovial
fibroblasts leading to formation of pannus [11,12], as
well as induces expression of chemokines and adhesion
molecules which play important role in the pathogenesis
of RA [13]. In most of the RA and PsA patients, neutra-
lization of pro-inflammatory cytokines improve the dis-
ease condition but there are some patients who do not
respond to this therapy [14,15]. This indicates that there
are other cytokines and growth factors, which may play
important roles in the disease process.
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IL-22, a newly discovered Th17 cytokine belongs to
cytokine of IL-10 family, however differs from other
cytokines of IL-10 family by being a potent proliferative
and inflammatory agent for different cell lines [16-20].
Activated T cells of Th17 and Th22 subsets are the
major source of IL-22 [21-24]. Apart from activated T
cells, IL-22 can be produced by natural killer (NK) cells
also [25]. IL-22 acts through IL-22 receptor, which is a
complex of IL-22R1 and IL-10R2 [26]. IL-10R2 is ubi-
quitously expressed whereas IL-22R1 is expressed in
liver, colon, small intestine, pancreas, kidney, skin and
fibroblast like synoviocytes of joints [20,27]. In the
pathogenesis of various autoimmune diseases such as
psoriasis and RA, the role of IL-22 has been established
[18-20,28]. Moreover, in collagen induced arthritis ani-
mal model, IL-22 has been found to play an important
role in pannus formation as well as in osteoclastogenesis
[29].
There is only one study which reported elevated levels
of IL-22 in synovial fluid (SF) of PsA patients [30]. To
our knowledge, there is no reported study on functional
role of IL-22 in PsA. In this study we investigated the
functional role of IL-22 in PsA. We measured IL-22
levels in serum and synovial fluid (SF) of PsA, RA and
OA. To determine the functional significance, we evalu-
ated the proliferative effect of human recombinant IL-22
(rIL-22) on fibroblast like synoviocytes (FLS) isolated
from PsA synovial tissue. Expression of functional
receptor of IL-22, IL-22Ra1 was determined at protein
level in FLS. Further we examined the inhibitory effect




This study was approved by the Institutional Review
Board (IRB) of Veterans Affairs Medical Centre
(VAMC), Sacramento. After obtaining IRB approved
informed consent form, specimens were collected from
patients with active PsA, RA and OA. RA and OA
patients were recruited according to the clinical, labora-
tory and radiographic classification criteria of the Amer-
ican College of Rheumatology (ACR). Patients with PsA
had either oligoarthritis or symmetric polyarthritis as
described by Moll and Wright [31]. All patients with
PsA fulfilled the CASPAR classification criteria for PsA
[32]. Before enrolling in this study, patients had under-
gone complete physical examination, evaluation of
severity of psoriasis and arthritis, appropriate blood tests
and radiological studies. Active PsA or RA was defined
by the presence of at least 3 swollen and 3 tender joints.
In patients with PsA, in addition to the above, presence
of plaque psoriasis with a qualifying lesion of at least 2
cm in diameter was checked. All patients were evaluated
for the swollen joint count, the tender joint count,
patient’s assessment of pain, ESR and CRP.
SF and blood were collected from patients with PsA (n
= 15), RA (n = 15) and OA (n = 15). Synovial fluid
mononuclear cells (SFMC) and peripheral blood mono-
nuclear cells (PBMC) were isolated from SF and blood
respectively. SF and synovial tissues were collected from
one or both knees of PsA, RA and OA patients. Synovial
tissues were studied from PsA (n = 5), RA (n = 5) and
OA (n = 5) patients. These subjects had an arthroscopic
procedure or joint replacement for treatment of their
arthritis. All enrolled patients were on NSAID or Aceta-
minophen except two RA patients were on low dose
oral steroid (≤ 7.5 mg/day), six RA patients were on
hydroxychloroquine; six RA and five PsA patients were
on low dose methotrexate (< 10 mg/week). None of the
PsA patients was on steroid. None of the RA or PsA
patients was on biologics for at least 3 months before
the enrollment for this study.
ELISA of IL-22 in synovial fluid (SF) and serum of patients
with PsA, RA and OA
Peripheral blood and SF from the knee joints of patients
with PsA (n = 15), RA (n = 15) and OA (n = 15) were
collected. The SF was immediately centrifuged at 1600
rpm for 20 min at 4°C to remove cells and debris. SF
supernatants were carefully removed and stored at -20°
C for ELISA of IL-22 (Human IL-22 ELISA Kit,
eBioscience, San Diego, CA, USA). Serum was stored at
-20°C for ELISA of IL-22. Sensitivity for IL-22 detection
by this kit is 8-1000 pg/ml.
Functional role of human rIL-22 in FLS of patients with
PsA
1. Isolation of FLS from synovial tissue
Fibroblast like synoviocytes (FLS) were isolated from
synovial tissue biopsies of PsA (n = 5), RA (n = 5) and
OA (n = 5) according to our standardized protocol
[33,34]. FLS were cultured in DMEM (Mediatech, Man-
assas, VA, USA), supplemented with sodium pyruvate
(Mediatech, Manassas, VA, USA), penicillin and strepto-
mycin (Axenia BioLogix, Dixon, CA, USA) and 10% (v/
v) fetal bovine serum (Axenia BioLogix, Dixon, CA,
USA) (complete DMEM) at 37°C in a humidified atmo-
sphere of 95% air and 5% CO2. After the third passage,
all FLS were examined for the fibroblast specific mar-
kers ASO2 (EMD4Biosciences, San Diego, CA, USA)
and CD55 (BD Pharmingen, San Diego, CA, USA). No
expression of the macrophage specific marker CD68
(BD Pharmingen, San Diego, CA, USA) or pan endothe-
lial cell adhesion molecule (PECAM), CD31 (BD Phar-
mingen, San Diego, CA, USA) were detected in FLS
cultures, thus excluding possible contamination of syno-
vial fibroblasts by synovial macrophages and endothelial
Mitra et al. Arthritis Research & Therapy 2012, 14:R65
http://arthritis-research.com/content/14/2/R65
Page 2 of 10
cells. All experiments were performed with cells
between 3rd and 6th passages.
2. Proliferative effect of human rIL-22 in FLS of PsA, RA and
OA patients
The proliferative effect of human rIL-22 (eBioscience, San
Diego, CA, USA) in FLS of PsA, RA and OA patients was
assessed in vitro by MTT assay and Carboxy fluorescein
succinimidyl ester (CFSE) dilution assay.
a. MTT assay- FLS from PsA (n = 5), RA (n = 5)
and OA (n = 5) were used to determine the IL-22
induced proliferative effect. Human recombinant
TNF-a (rTNF-a) was used as a positive control for
proliferation assays [11,12]. We performed dose
response curve and observed that human rIL-22 at
100 ng/ml, human anti IL-22R antibody (IL-22R Ab.,
R&D Systems, Minneapolis, MN, USA) at 1000 ng/
ml and human rTNF-a (eBioscience, San Diego, CA,
USA) at 20 ng/ml showed optimum response. We
used these concentrations in subsequent experi-
ments. Third to sixth passage FLS (20,000 cells/well)
were cultured in triplicate in 24 well plate for 5 days
with medium only, rIL-22 (100 ng/ml), IL-22R Ab
(1000 ng/ml), IL-22R Ab (1000 ng/ml) + rIL-22 (100
ng/ml), rTNF-a (20 ng/ml) and rIL-22 (100 ng/ml)
+ rTNF-a (20 ng/ml). MTT assay was done as per
our standardized protocol [34]. Briefly, MTT (Sigma,
St. Louis, MO, USA) 5 mg/ml was added to each
well followed by incubation for 4 hours. Acid-isopro-
panol (0.04 N HCl in isopropanol, 100 μl/well) was
added and plates were maintained at room tempera-
ture for 5 minutes. The optical density was mea-
sured using a microtiter plate reader at 570/690 nm.
b. Carboxy fluorescein succinimidyl ester (CFSE)
dilution assay- We used Cell Trace CFSE cell prolif-
eration kit (Molecular Probes, Eugene, OR, USA).
For this assay, we seeded 2 × 105 FLS in T25 flask
and stained them with CFSE (2 μM) followed by
incubation with media only, rIL-22 (100 ng/ml),
rTNF-a (20 ng/ml) and rIL-22 (100 ng/ml) + rTNF-
a (20 ng/ml) for 5 days. CFSE dilution was evaluated
by flow cytometry (FACScalibur, BD Biosciences,
San Jose, CA, USA). Data were analyzed using
FlowJo software (Treestar, Ashland, OR, USA).
Western blot analysis of IL-22Ra1 expression in FLS of
PsA, RA and OA
FLS of PsA, RA and OA were grown in T75 flask and
upon 70-80% confluence, cells were scrapped with a cell
scrapper, then centrifuged for 8 min at 1600 rpm, 22°C.
Lysis buffer containing 150 mM NaCl (Fischer Scientific,
Houston, TX, USA), 50 mM Tris-HCL of pH 7.2
(Sigma-Aldrich, St. Louis, MO, USA), 1% w/v Triton X-
100 (Sigma-Aldrich, St. Louis, MO, USA), 1% w/v
sodium deoxycholate (Sigma-Aldrich, MO, USA), 0.1%
w/v SDS (Fischer Scientific, Houston, TX, USA) with
protease inhibitor (Roche, Indianapolis, IN, USA) was
added and incubated for 40 min at 4°C. Supernatants
were collected after centrifugation at 4°C, 13000 rpm for
20 min and the protein concentration was estimated
using BCA Protein Assay Reagent Kit (Thermo-Fisher
scientific, Houston, TX, USA). Cell lysate protein (30
μg) was used for western blot analysis. Cell lysate was
run in a 10% acrylamide gel (BIO-RAD, CA, USA). The
Immuno-Blot PVDF membrane (BIO-RAD, Richmond,
CA, USA) was blocked with 5% nonfat dried milk in
TBST (50 ml of 1 M Tris, 30 ml of 3 M NaCl, 20 ml of
10% Tween, ddH2O, total volume 1L) for 2 hour at
room temperature. Then blots were incubated overnight
at 4°C with the primary antibody, IL-22Ra1 (R&D
Sytems, Minneapolis, MN, USA) at 3 μg/ml concentra-
tions; atubulin (Cell signaling Technologies, Danvers,
MA, USA), 1:250 concentrations. Blots were washed 5x
in TBST and secondary antibody (Jackson Immunore-
search Labs, PA, USA) was added at 1:5000 dilution.
After keeping the blot in secondary antibody for 1 hr, it
was washed 5x in TBST and then developed using ECL
western blotting detection reagents solution (Thermo-
Fisher Scientific, Houston, TX, USA) for chemilumines-
cent detection. Band density was measured using Image
J software (NIH, Bethesda, MD, USA).
Inhibitory effect of human anti IL-22R antibody (IL-22R
Ab) on rIL-22 induced FLS proliferation
FLS (20,000/well) were seeded in a 24-well plate with 1
ml of complete DMEM (DMEM, 10%FBS, antibiotics).
Cells were pre-treated with IL-22R Ab (1000 ng/ml) for
1 hr at 37°C then human rIL-22 (100 ng/ml) was added
and incubated at 37°C in CO2 incubator for 5 days.
MTT assay was done to determine the inhibitory effect
of IL-22R Ab on IL-22 induced FLS proliferation.
Source of IL-22
To determine the source of IL-22, SFMC and PBMC
isolated from SF and peripheral blood of PsA (n = 15),
RA (n = 15) and OA (n = 15) were examined. PBMCs
were isolated by Ficoll-hypaque gradient (GE Healthcare,
Piscataway, NJ, USA) centrifugation of peripheral blood.
Synovial fluid was treated with hyaluronidase enzyme
(Sigma-Aldrich, MO, USA) at 1 mg/ml concentration
for 5 mins at room temperature, then centrifuged at
2000 rpm for 20 min at 4°C. Cell pellet were resus-
pended in 1 ml of RPMI 1640 (Mediatech, Manassas,
VA, USA) complete media (RPMI-1640 containing 10%
FBS, antibiotics). Then the CD3+ T cells were separated
magnetically from SFMC and PBMC using Easy Sep
negative selection human T cell enrichment kit (Stem
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Cell Technology, Vancouver, BC, Canada) according to
manufacturer’s protocol and the purity was determined
by flow cytometry using human anti CD3 antibody (BD
pharmingen, San Diego, CA, USA). In a 24-well tissue
culture plate, 1 × 106 synovial CD3+ T cells and periph-
eral blood CD3+ T cells were seeded separately and sti-
mulated with 50 ng/ml of phorbol myristate acetate
(PMA) and 1 μg/ml of ionomycin (Sigma-Aldrich, MO,
USA) for 24 hrs and 10 μg/ml of phytoheamagglutinin
(PHA, Invitrogen, CA, USA) for 48 hrs. For mimicking
physiological stimulation, FLS were cultured in 24-well
plates coated with human anti CD3 and anti CD28 (5
μg/ml each) (BD Biosciences, San Diego, CA, USA) at
37°C. After 24 and 48 hrs, supernatant was collected
and IL-22 was measured in the supernatant by ELISA.
Statistical analysis
All experiments were done in triplicate. Results were
expressed as Mean ± SEM. For analysis of flow cyto-
metric data, we considered the % of divided cells of
each treatment group using the FlowJo software (TreeS-
tar Inc, Ashland, OR, USA). All data were analyzed sta-
tistically using the GraphPad Prism software version 5.0
(GraphPad Software Inc, La Jolla, CA, USA). Non-para-
metric tests (Wilcoxon matched pairs signed rank test,
Mann Whitney test, Friedman’s ANOVA, Kruskal Wallis
ANOVA with Dunn’s multiple comparison test) were
used to determine the statistical significance. A p value
< 0.05 was considered statistically significant.
Results
Synovial fluid IL-22 levels were elevated in PsA
IL-22 levels in SF of PsA (17.75 ± 3.46 pg/ml) were sig-
nificantly higher compared to that in OA (5.03 ± 0.39
pg/ml, p < 0.001, Kruskal-Wallis ANOVA with Dunn’s
multiple comparison test) (Figure 1). In SF of RA, high-
est concentration of IL-22 (21.06 ± 3.55 pg/ml) was
observed. However, there was no significant difference
of IL-22 levels between SF of PsA (17.75 ± 3.46 pg/ml)
and RA (21.06 ± 3.55 pg/ml). Serum IL-22 levels in
PsA, RA and OA were 9.22 ± 0.54 pg/ml, 9.64 ± 1.20
pg/ml and 4.45 ± 0.25 pg/ml respectively, p = ns, Krus-
kal Wallis ANOVA with Dunn’s multiple comparison
test (Figure 1). We found significantly higher levels of
IL-22 in SF of PsA (17.75 ± 3.46 pg/ml) and RA (21.06
± 3.55 pg/ml) compared to that in serum of PsA (9.22 ±
0.54 pg/ml) and RA (9.64 ± 1.20 pg/ml) (p < 0.01,
Mann Whitney test). In OA, there was no significant
difference of IL-22 levels between SF (5.03 ± 0.39 pg/
ml) and serum (4.45 ± 0.25 pg/ml).
Human rIL-22 induced marked proliferation of FLS
MTT and CFSE dilution assay were done to determine
the proliferative effect of human rIL-22 in FLS of PsA,
RA and OA. In MTT assay, significantly higher prolif-
eration of PsA derived FLS were observed with rIL-22
(OD: 1.27 ± 0.06) compared to media (OD: 0.53 ± 0.02,
p < 0.001, Friedman’s ANOVA with Dunn’s multiple
comparison test) (Figure 2A). In this experiment we
used rTNF-a as a positive control [11,12] and significant
proliferation were found with rTNF-a (OD: 1.53 ± 0.05)
compared to media (OD: 0.53 ± 0.02, p < 0.001, Fried-
man’s ANOVA with Dunn’s multiple comparison test).
There was no significant difference of proliferation
between the rIL-22 (OD: 1.27 ± 0.06) and rTNF-a (OD:
1.53 ± 0.05) treated FLS. Here we observed a novel find-
ing that rIL-22 induced significantly more proliferation
in presence of rTNF-a (OD: 2.06 ± 0.11) than rIL-22
alone (OD: 1.27 ± 0.06, p < 0.01) (Figure 2A).
We also did this experiment in RA FLS and observed
similar results; human rIL-22 (OD: 1.58 ± 0.05) and
rTNF-a (OD: 1.96 ± 0.04) induced significant prolifera-
tion compared to media (OD: 0.65 ± 0.04, p < 0.001,
Friedman’s ANOVA with Dunn’s multiple comparison
test). In RA also, rIL-22 in presence of rTNF-a (OD:
2.37 ± 0.11) induced significantly more proliferation
than rIL-22 alone (OD: 1.58 ± 0.05, p < 0.01). In OA
FLS, rIL-22 (OD: 0.73 ± 0.12) as well rTNF-a (OD: 0.90
± 0.16) induced significant proliferation compared to
media (OD: 0.38 ± 0.05, p < 0.05, Friedman’s ANOVA
with Dunn’s multiple comparison test).
We further confirmed the proliferative effect of human
rIL-22 on FLS by CFSE dilution assay. In this assay, simi-
lar results were found regarding proliferation of FLS with
rIL-22. In FLS of PsA, human rIL-22 (19.64 ± 3.13%) and
human rTNF-a (24.60 ± 4.95%) induced significantly
more proliferation compared to that in media only (5.58
± 0.98%, p < 0.01, Friedman’s ANOVA with Dunn’s mul-
tiple comparison test) (Figure 2B and 2C). Here also,
rTNF-a (24.60 ± 4.95%) showed more proliferation of
FLS than rIL-22 (19.64 ± 3.13%), but there was no signifi-
cant difference in proliferation of FLS between these two
groups. In this assay also, rIL22 in presence of rTNF-a
(30.76 ± 4.17%) showed more proliferation than rIL-22
alone (19.64 ± 3.13%, p < 0.05) (Figure 2B and 2C).
In RA patients also, rIL-22 (21.57 ± 3.33%) and rTNF-
a (27.45 ± 3.29%) induced significant proliferation com-
pared to that in media (6.43 ± 1.61%, p < 0.01, Fried-
man’s ANOVA with Dunn’s multiple comparison test).
There was no significant difference of proliferation
between rIL-22 and rTNF-a treated FLS. In RA also, we
observed that rIL-22 induced significantly more prolif-
eration of FLS in presence of rTNF-a (33.11 ± 2.42%)
compared to rIL-22 alone (21.57 ± 3.33, p < 0.05).
IL-22Ra1 was expressed in FLS
IL-22Ra1 expression at protein level was done by wes-
tern blotting. Expressions of IL-22Ra1 were found in
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FLS of PsA, RA and OA patients (Figure 3A). The rela-
tive intensity (R.I) of IL-22Ra1 in FLS of PsA, RA and
OA patients was 0.92 ± 0.07, 0.94 ± 0.16 and 0.69 ±
0.18 respectively. There was no significant difference
(Kruskal Wallis ANOVA with Dunn’s multiple compari-
son test) in expressions of IL-22Ra1 between FLS of
PsA, RA and OA patients (Figure 3B).
Inhibitory effect of anti IL-22R antibody on rIL-22 induced
FLS proliferation
In MTT assay, there was a significant difference of pro-
liferation between media (OD: 0.53 ± 0.02) and IL-22 +
IL-22R Ab (OD: 0.76 ± 0.03, p < 0.05) treated FLS (Fig-
ure 4). Anti IL-22R (IL-22R Ab) antibody (OD: 0.76 ±
0.03) significantly inhibited the rIL-22 induced FLS pro-
liferation in PsA (1.27 ± 0.06, p < 0.01, Friedman ’s
ANOVA with Dunn’s multiple comparison test) (Figure
4). There was no significant difference of proliferation
between media (OD: 0.53 ± 0.02) and only IL-22R Ab
(OD: 0.63 ± 0.03) treated FLS.
In FLS of RA also, IL-22R Ab (OD: 0.71 ± 0.03) signif-
icantly inhibited rIL-22 induced FLS proliferation (OD:
1.58 ± 0.05, p < 0.001, Friedman’s ANOVA with Dunn’s
multiple comparison test. There was no significant dif-
ference of proliferation between media (OD: 0.65 ±
0.04) and only IL-22R Ab. (OD: 0.71 ± 0.03) treated
FLS. In OA FLS, IL-22R Ab (OD: 0.49 ± 0.02) inhibited
the rIL-22 induced proliferation (OD: 0.73 ± 0.12, p =
ns), but there was no significant difference.
Synovial fluid of PsA and RA patients are enriched with
IL-22 producing CD3+ T cells
CD3+ T cells were obtained from synovial fluid and per-
ipheral blood of PsA, RA and OA by magnetic bead
p < 0.001 
p < 0.001 
p < 0.01 
p < 0.01 
Figure 1 IL-22 in SF and serum of PsA and RA were elevated compared to OA patients. Synovial fluid (SF) and peripheral blood (PB) were
collected from psoriatic arthritis (PsA, n = 15), rheumatoid arthritis (RA, n = 15) and osteoarthritis (OA, n = 15) patients. IL-22 levels were
measured in SF and serum samples by ELISA. All experiments were done in triplicate. Results were expressed as Mean ± SEM. Nonparametric
tests; Mann Whitney and Kruskal Wallis ANOVA with Dunn’s multiple comparison tests were used to determine statistical significance.
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Figure 2 Human rIL-22 induced marked proliferation of FLS in PsA patients. FLS were isolated from synovial tissue of patients with
psoriatic arthritis (PsA, n = 5). (A) FLS (20,000 cells/well) of PsA patients were seeded in a 24-well plate in triplicate and incubated for 5 days at
37°C in presence or absence of human rIL-22 (100 ng/ml), human rTNF-a (20 ng/ml) and combination of rIL-22 (100 ng/ml) + rTNF-a (20 ng/ml).
FLS used in these experiments were between 3rd and 6th passage. MTT assay was done to determine FLS proliferation and results were
expressed as Mean ± SEM of OD. (B) FLS (2 × 105 cells) of PsA patients were seeded in T25 flask in triplicate, stained with CFSE (2 μM) and
incubated for 5 days at 37°C in presence or absence of human rIL-22 (100 ng/ml), human rTNF-a (20 ng/ml) and combination of rIL-22 (100 ng/
ml) + rTNF-a (20 ng/ml). Data were acquired in FACScalibur flow cytometer and analysis was done using FlowJo software. Proliferation was
measured in terms of percent of divided cells and data were expressed as Mean ± SEM. The bar diagram represents the percent divided cells of
FLS in PsA patients. (C) A representative histogram showing the proliferative effect of different treatments (rIL-22, rTNF-a, rIL-22 + rTNF-a)
compared to media in FLS obtained from PsA patients. Non parametric test, Friedman’s ANOVA with Dunn’s multiple comparison test was done
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Figure 3 Western blot analysis of IL-22Ra1 expression in FLS of PsA, RA and OA patients. Expression of IL-22Ra1 in FLS isolated from PsA
(n = 5), RA (n = 5) and OA (n = 5) patients was assessed. (A) A representative western blot showing expression of IL-22Ra1 in PsA, RA and OA
patients. (B) A bar diagram showing relative intensity (R.I) of IL-22Ra1 expression in FLS obtained from PsA, RA and OA patients. Results were
expressed as Mean ± SEM. Non parametric test, Kruskal Wallis with Dunn’s multiple comparison test was done to determine the statistical
significance.
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sorting. The purity of enriched T cells was > 90% by
flow cytometric analysis. Activated synovial T cells of
PsA and RA produced significantly more IL-22 than
that of OA. Moreover in PsA and RA, activated synovial
T cells produced significantly more IL-22 than periph-
eral blood T cells of same patients [Table 1].
Discussion
Several reports suggest that IL-22, a relatively new Th17
cytokine plays a critical role in the inflammation and
proliferation cascade of various autoimmune diseases
like rheumatoid arthritis and psoriasis [16-20,35,36]. In
psoriasis, a correlation between serum IL-22 level and
psoriasis area and severity index (PASI) score has been
observed [28]. Higher levels of IL-22 were found in
synovial fluid of PsA and RA patients [30,37]. Moreover
systemic as well as intra-articular anti-TNF therapy
showed reduction of increased IL-22 level in serum and
synovial fluid of psoriasis and PsA patients respectively
[30,38]. To our knowledge, there is no report available
on the role of IL-22 in PsA. In this study we demon-
strated the functional significance of IL-22 in PsA.
We observed significantly elevated levels of IL-22 in SF
of PsA (17.75 ± 3.46 pg/ml) compared to OA (5.03 ±
0.39 pg/ml). We found highest concentration of IL-22 in
SF of RA (21.06 ± 3.55 pg/ml), but it was not signifi-
cantly different from PsA (17.75 ± 3.46 pg/ml) (Figure 1).
Most of the reports demonstrated T cells as a major
source of IL-22 [18,21,22]. In addition NK cells have
been reported to produce IL-22 [25] and there is one
report where IL-22 was identified in FLS of RA synovial
tissues [20]. Here we showed that activated synovial
CD3+ T cells of PsA and RA produced more IL-22 than
those of OA [Table 1]. Synovial fluid from healthy
p < 0.05 
p < 0.01 
Figure 4 Human anti IL-22R antibody significantly inhibited rIL-22 induced FLS proliferation in PsA. FLS were pretreated with anti IL-22R
antibody (1000 ng/ml) for 1 hr then incubated with rIL-22 (100 ng/ml) at 37°C for 5 days. MTT assay was done to evaluate the inhibitory effect
of anti IL-22R antibody (IL-22R Ab). Each experiment was done in triplicate. Results were expressed as Mean ± SEM of OD. Non parametric test,
Friedman’s ANOVA with Dunn’s multiple comparison test was done to determine statistical significance.
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volunteers could not be obtained. We chose osteoarthri-
tis patients (OA), a non-inflammatory arthritis as a
negative control. Moreover we observed that activated
synovial T cells produced significantly more IL-22 com-
pared to activated peripheral blood T cells of same
patients [Table 1].
In RA, it had been shown that rIL-22 induced marked
proliferation of FLS and IL-22 receptors (IL-22R1) were
present in those FLS [20]. In this study, we demon-
strated that human rIL-22 induced significant prolifera-
tion of FLS of PsA and IL-22Ra1 were expressed in PsA
FLS (Figure 2A, B and 3A). We also confirmed the
expression of IL-22Ra1 in FLS of RA and OA [20].
There was no significant difference in IL-22Ra1 expres-
sions among PsA, RA and OA FLS (Figure 3B). We
observed more proliferation of FLS with rTNF-a in
comparison to rIL-22, however there was no significant
difference (Figure 2A and 2B). We also showed that the
rIL-22 induced proliferation of FLS is inhibited by IL-
22R antibody in PsA (Figure 4). These observations sug-
gest that functionally active IL-22 is present in increased
amount in the SF of PsA.
We observed a novel finding in PsA and RA that com-
bination of rTNF-a and rIL-22 induced significantly
more proliferation of FLS than rIL-22 alone (Figure 2A
and 2B). In few studies on human keratinocytes, it have
been shown that IL-22 together with TNF-a produce
synergistic effect in terms of secretion of antimicrobial
peptides and chemokines [39,40] however to our knowl-
edge there is no study showing the combined effect of
IL-22 and TNF-a on the proliferation of FLS. In this
study we did not elucidate the mechanism responsible
for this combined effect of IL-22 with TNF-a in FLS
proliferation. Both TNF-a and IL-22 exert proliferative
effect by inducing phosphorylation of extracellular signal
regulated kinases (ERK)/p38 MAPK [20,41]. In a study
on keratinocytes, Eyerich et al showed the synergistic
effect of IL-22 and TNF-a on induction of immune
genes by phosphorylation of different MAPK specially
p38 [39]. Thus it is possible that combination of IL-22
and TNF-a induce more phosphorylation of Erk/MAPK
pathway than either of IL-22 or TNF-a alone resulting
in more proliferation of FLS.
Conclusions
To summarize, in this study we observed significantly
elevated levels of IL-22 in synovial fluid of PsA com-
pared to OA patients and activated synovial T cells pro-
duced more IL-22 than activated peripheral blood T
cells in PsA. IL-22 is functionally active since it induced
significant proliferation of FLS. Thus IL-22 has the
potential to contribute in the pannus formation. More-
over, IL-22 in combination with TNF-a induced signifi-
cantly more proliferation of FLS than IL-22 or TNF-a
alone which provides a new insight in the pathogenesis
of PsA. Here we have also shown that the IL-22 induced
FLS proliferation can be blocked significantly by anti IL-
22R antibody. Thus, IL-22/IL-22R system may be a
potential novel target of drug development for psoriatic
arthritis.
Abbreviations
CFSE: carboxy fluorescein succinimidyl ester; ELISA: enzyme-linked
immunosorbent assay; FLS: fibroblast like synoviocytes; MTT: [3-(4,5-
Table 1 IL-22 production by activated synovial fluid (SF) and peripheral blood (PB) CD3+ T cells.
IL-22 concentration (pg/ml)




















3.85 ± 0.51 14.57 ± 0.80*$ 18.92 ± 0.89**#$ 4.21 ± 0.5 95.55 ± 7.81***#$
PB-T
cells






4.22 ± 0.31 14.32 ± 0.96*$ 18.91 ± 1.97**#$ 4.63 ± 0.37 81.63 ± 5.90***#$
PB-T
cells





4.63 ± 0.57 8.61 ± 0.79 13.59 ± 0.81* 4.79 ± 0.12 39.06 ± 3.92***
PB-T
cells
3.94 ± 0.22 6.88 ± 0.34 11.44 ± 0.78* 4.04 ± 0.18 32.78 ± 2.56***
* p < 0.05, **p < 0.01, compared to 24 hr unstimulated media; ***p < 0.001, compared to 48 hr unstimulated media, Wilcoxon matched pairs signed rank test. #p
< 0.05, compared to PB-T cells; $p < 0.05, $$p < 0.01, compared to that of OA, Mann Whitney test.
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Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide]; ns: not significant;
OA: osteoarthritis; OD: optical density; PB: peripheral blood; PBMC: peripheral
blood mononuclear cells; PHA: phytohaemagglutinin; PMA: phorbol
myristate acetate; PsA: psoriatic arthritis; RA: rheumatoid arthritis; rIL-22:
recombinant interleukin 22; rTNF-α: recombinant tumor necrosis factor alpha;
SF: synovial fluid; SFMC: synovial fluid mononuclear cells.
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